Despite reshaping obesity treatment, GLP-1 receptor agonists have remained out of reach for Medicare Part D beneficiaries seeking coverage for weight loss
Researchers describe this as a quiet liberation
To function, a muscle cell uses more energy than a fat cell, so, if you lose muscle mass, your body burns fewer calories overall, and daily calorie intake should be adjusted
Theyre targeting the metabolic dysfunction that sits at the center of many chronic conditions
Tirzepatide, sold as Zepbound and Mounjaro, and semaglutide, under the brand names Wegovy and Ozempic, have become wildly popular for weight loss and have demonstrated other health benefits, such as heart-protective properties
But what if you could take those benefits further